{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":4,"sponsored":0,"items":[{"id":"n_o3jxladalhymp47wn2la","seq":1340785,"kind":"article","title":"Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion","url":"https://www.themarketsdaily.com/2026/10/02/sanofi-regeneron-expand-dupixent-alliance-in-deal-worth-up-to-e8-billion.html","published":"2026-10-02T12:29:03Z","seen":"2026-10-02T12:29:03Z","lang":"en","source":{"id":"themarketsdaily.com","name":"themarketsdaily.com","domain":"themarketsdaily.com"},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["Tristan Rich"],"entities":[{"id":"Q158205","name":"Sanofi","type":"org"},{"id":"Q97159313","name":"Dupixent","type":"other"}],"story":"st_qmf7wphactmtbbj6ilqq","category":"economy-business","category_p":0.72,"sentiment":"positive","tone":0.16,"political":0.24},{"id":"n_dvv2rlhkwi4vkz5yqi3q","seq":1240266,"kind":"article","title":"한 달에 한 번으로 '듀피젠트' 넘을까…화이자, 아토피 맞대결","title_en":"Will 'Dupixent' be surpassed by once-a-month... Pfizer, Dupixent face off in atopic dermatitis","url":"https://www.medipana.com/news/articleView.html?idxno=418643","summary":"화이자가 4주마다 투여하는 아토피피부염 신약 후보물질의 임상 성적을 공개하고, 기존 치료제 \\'듀피젠트\\'와 직접 비교하는 후기 임상을 진행하고 있다. 세 가지 염증 신호를 동시에 차단하는 삼중특이항체를 앞세워 효과와 투여 편의성을 함께 높일 수 있을지 주목된다. 글로벌 빅파마 화이자는 1일(현지시간) 오스트리아 빈에서 3일까지 열리는 유럽피부과학회(EADV) 연례학술대회에서 \\'틸레키미그(tilrekimig·PF-07275315)\\'의 중등도·중증 성인 아토피피부염 임상 2상 상세 결과를 발표했다. 틸레키미그는 인터루킨-4(IL-4),","published":"2026-10-01T23:23:01Z","seen":"2026-10-02T00:25:40Z","lang":"ko","source":{"id":"kite-cdn-medipana-com-912f9c","name":"cdn.medipana.com","domain":"cdn.medipana.com"},"via":"kite-cdn-medipana-com-912f9c","topics":["medicine","파마시안"],"authors":["최봉선 기자"],"entities":[{"id":"Q97159313","name":"Dupixent","type":"other"},{"id":"Q206921","name":"Pfizer","type":"org"}],"story":"st_dvv2rlhkwi4vkz5yqi3q","category":"health","category_p":0.5,"sentiment":"neutral","tone":-0.12,"political":0.02},{"id":"n_54ktn4p4ztaqizlnccxq","seq":1227602,"kind":"article","title":"Recon: Sanofi, Regeneron expand partnership after Dupixent success; Lilly amylin-Zepbound combo succeeds in mid-stage trial","url":"https://www.raps.org/resource/recon-sanofi-regeneron-expand-partnership-after-dupixent-success-lilly-amylin-zepbound-combo-succeeds-in-mid-stage-trial.html","published":"2026-10-01T19:50:00Z","seen":"2026-10-01T22:23:18Z","lang":"en","source":{"id":"raps.org","name":"raps.org","domain":"raps.org"},"via":"gdelt-gkg-english","topics":["health","economy"],"entities":[{"id":"Q158205","name":"Sanofi","type":"org"},{"id":"Q97159313","name":"Dupixent","type":"other"},{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q108324770","name":"tirzepatide","type":"other"}],"story":"st_7jv5rchntqf2sr24tvoa","category":"health","category_p":0.47,"sentiment":"positive","tone":0.74,"political":0.03},{"id":"n_7jv5rchntqf2sr24tvoa","seq":1066006,"kind":"article","title":"STAT+: Sanofi, Regeneron expand partnership after Dupixent success","url":"https://www.statnews.com/2026/10/01/sanofi-regeneron-agreement-dupixent-antibodies-immunology","summary":"Sanofi and Regeneron have re-upped their collaboration pact, aiming to build on the blockbuster success of the drug Dupixent.","published":"2026-10-01T06:16:27Z","seen":"2026-10-01T06:17:33Z","lang":"en","country":"US","source":{"id":"kite-statnews-com-aa5345","name":"statnews.com","domain":"statnews.com","outlet":{"wikidata":"Q28452506","name":"Stat","type":"website","designations":["business","news website","website"]}},"via":"kite-statnews-com-aa5345","topics":["healthcare","usa","medicine","pharma","drug development","pharmaceuticals","stat+"],"authors":["Andrew Joseph"],"entities":[{"id":"Q158205","name":"Sanofi","type":"org"},{"id":"Q97159313","name":"Dupixent","type":"other"}],"image":"https://www.statnews.com/wp-content/uploads/2026/07/GettyImages-2281597952-645x645.jpg","mentions":2,"story":"st_7jv5rchntqf2sr24tvoa","category":"economy-business","category_p":0.42,"category2":"health","sentiment":"positive","tone":0.62,"political":0.03}]}